Venture Medical announced as the exclusive US distributor of Vendaje AC ®

Oct 28, 2024
Venture Medical announced as the exclusive US distributor of Vendaje AC ®

Venture Medical, LLC has been announced as the exclusive distributor of Vendaje AC®, a wound care product manufactured by BioStem Technologies Inc. (OTC: BSEM).

Venture Medical, LLC has been announced as the exclusive distributor of Vendaje AC®, a wound care product manufactured by BioStem Technologies Inc. (OTC: BSEM).

MISSOULA, MT, UNITED STATES, October 29, 2024 /EINPresswire.com/ -- Venture Medical, LLC, an innovative solutions provider in the U.S. wound care market with an extensive wound care-focused team, has been announced as the exclusive distributor of Vendaje AC®, a placental derived advanced wound care product manufactured by BioStem Technologies Inc. (OTC: BSEM).

John Schroeder, President of Venture Medical, LLC, explained the significance of this action. “With countless graft products available today, we’re proud to partner with BioStem Technologies, a company that prioritizes clinical efficacy in everything they do. Vendaje AC®, manufactured using the innovative BioREtain®process, retains the critical elements of placental tissue—structural components, growth factors, and anti-inflammatory cytokines—that are essential for effective wound healing. This breakthrough allows us to offer healthcare providers and Medicare beneficiaries a powerful, reimbursable solution tailored to meet the needs of patients with non-healing wounds. Together, we’re bringing a meaningful solution to those who need it most.”

Jason Matuszewski, CEO of BioStem Technologies Inc., stated  “This is a pivotal moment for BioStem Technologies. With nationwide Medicare reimbursement, Vendaje AC®becomes our second product available to patients across all 50 states. The launch of Vendaje AC®underscores our commitment to delivering innovative wound care solutions for patients suffering from chronic, non-healing wounds. We're excited to collaborate with Venture Medical once again, whose partnership was instrumental in the success of AmnioWrap2®. Together, we’re expanding access to cutting-edge treatments that make a real difference in patient outcomes.”

Mr. Schroeder added, “We are excited to continue building a robust foundation of clinical evidence by collaborating with healthcare providers to showcase their results, including several published retrospective studies, upcoming whitepapers, and formal clinical studies in the coming months. These efforts will help demonstrate the effectiveness and unique benefits of our BioREtain process and its innovative products, such as Vendaje AC®, distinguishing them from other solutions available in the market. We are confident that as more healthcare professionals see the value of our products, we will achieve widespread adoption across the United States. Our commitment to rigorous clinical validation underscores our dedication to advancing patient care and setting new industry standards.”

Available through a healthcare provider in all 50 states, Vendaje AC®offers patients who are experiencing non-healing wounds an advanced treatment option that acts as a protective barrier or covering to provide an optimal environment for wound healing and closure.

Healthcare providers or patients interested in learning more about Vendaje AC®allografts can visit:
https://biostemtechnologies.com/vendaje-ac-2/

About Venture Medical, LLC: Venture Medical is a groundbreaking healthcare services company with a decade-long history of innovation, dedication, and consistent growth in the field of wound care and healing. Over the past 15 years, Venture Medical has expanded its reach across the United States and has grown to become a leading master distributor and reseller and software services provider for manufacturers and end users of biologics, advanced diagnostics, durable medical equipment, and capital goods.

For more information, visit venturemedical1.com and follow us on LinkedIn

About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain®processing method. BioREtain®has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA-registered and AATB-accredited site in Pompano Beach, Florida.

More News & Updates

Stay Up-To-Date With
Venture Medical

Mar 11, 2025

Open Wound Research and Venture Medical Announce Collaboration to Advance Pressure Ulcer Research

Feb 12, 2025

Innovation & Adaptability: An Interview with the CEO of Venture Medical,LLC

In an industry where innovation and adaptability are key, Venture Medical, LLC has carved out a unique space, blending bold ambition with a steadfast commitment to quality and service. Over the past few years, the company has experienced exponential growth, but what truly sets Venture apart isn’t just its expansion—it’s the culture, leadership philosophy, and relentless pursuit of excellence that fuel its success.

Jan 15, 2025

The LCD Is Frozen, Now What?

On Monday during his first day in office, President Trump signed an Executive Order (EO) freezing the pending LCD policy that would limit access to skin substitutes for chronic wound care. To be clear - this is a policy freeze pending further action.

Jan 1, 2025

The Scrutiny on Skin Substitutes: Shifting The Focus From Medicare Advantage

While the top six major insurance companies have reported soaring profits—some rising by thousands of percentage points since the Medicare Advantage program was enacted, many patients enrolled in Medicare Advantage plans claim they didn’t even realize they were leaving traditional Medicare. This lack of transparency raises important questions about how these plans are marketed and the tactics used to encourage patients to switch.

Oct 21, 2024

The Rising Costs of Wound Care: Finding Solutions Without Sacrificing Access

Under a system previously reliant solely on hospital outpatient departments, many patients—especially the elderly in care facilities, the poor, the homebound, the rural, and the otherwise disenfranchised—never enjoyed equitable access. Today, however, more patients than ever are receiving wound care as providers are motivated to bring advanced modalities directly to them.

Jan 24, 2024

MicroGen Diagnostics in Chronic Wounds

“Explore the fascinating realm of microbiology and healthcare in the MicroGenDX Mic’d Up podcast, hosted by Rick Martin, CEO of MicroGenDX. Join Rick and his special guest, the esteemed Caroline Fife, MD, FAAFP, CWS, Professor of Medicine at Baylor College of Medicine

Dec 14, 2023

Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions

The national ASP publication of AmnioWrap2™ knocks down barriers that will provide healthcare professionals and their patients with the opportunity to use AmnioWrap2™, a superior wound care product for certain applications.

Sep 7, 2022

The Gap Between Clinical Trials and Real-World Chronic Wound Patients

Caroline Fife, M.D. highlights a concerning discrepancy between the characteristics of patients with chronic wounds in real-world settings and those selected for clinical trials.

Sep 1, 2022

Demonstration of the Venture Medical Sacral Dressing Kit

Get a first-hand look at the application process of the Venture Medical Sacral Dressing Kit in this short video. We illustrate the kit's key role in protecting wounds from contaminants for patients with pressure ulcers who also suffer from incontinence. The demonstration also highlights how this kit supports the performance of advanced treatments such as CTPs. Learn to enhance your wound care practices and promote better wound healing with this cutting-edge solution.